Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · IEX Real-Time Price · USD

12.26

+0.21 (1.74%)

At close: Jul 2, 2024, 3:55 PM

12.50

+0.24 (1.96%)

After-hours: Jul 2, 2024, 7:58 PM EDT

Avalo Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-31.54	-41.66	-84.38	-63.5	-16.07	Upgrade
Depreciation & Amortization	0.16	0.17	1.66	1.84	3.88	Upgrade
Share-Based Compensation	3.48	7.55	8.17	6.79	2.53	Upgrade
Other Operating Activities	-2.77	7.19	3.66	14.33	-9.48	Upgrade
Operating Cash Flow	-30.68	-26.75	-70.89	-40.54	-19.13	Upgrade
Capital Expenditures	-0.13	-0.1	-0.11	-0.06	-0.26	Upgrade
Acquisitions	0	0	0	11.2	-0.18	Upgrade
Investing Cash Flow	-0.13	-0.1	-0.11	11.13	-0.44	Upgrade
Share Issuance / Repurchase	46.29	-14.7	73.86	44.88	13.73	Upgrade
Debt Issued / Paid	-21.24	0	32.9	0	-0.26	Upgrade
Other Financing Activities	-	-	-	-0.09	-0.92	Upgrade
Financing Cash Flow	25.04	-14.7	106.76	44.78	12.56	Upgrade
Net Cash Flow	-5.77	-41.55	35.76	15.38	-7.02	Upgrade
Free Cash Flow	-30.81	-26.85	-71.01	-40.6	-19.4	Upgrade
Free Cash Flow Margin	-1601.51%	-148.72%	-1315.39%	-606.09%	-287.34%	Upgrade
Free Cash Flow Per Share	-38.44	-684.40	-1820.68	-1560.99	-1266.51	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).